Xtandi (Enzalutamide) Patent Expiration, LOE Window & CMS Spending

Xtandi (Enzalutamide) by Astellas Pharma: FDA Orange Book core substance LOE 2027-08-13 (last listed 2037-02-23), 1 AB generics, $3.55B 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstellas Pharma
FDA Application & PathwayN203415 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2027-08-13
Last Listed Patent or Exclusivity Date2037-02-23
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$3.55B
2024 Medicare Part D Spend$3.40B
2024 Medicaid Spend$151.2M
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 16.8% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Astellas Pharma across sibling Meru public-data platforms.